lutetium Lu 177 rsopatamab tetraxetan

{
  "id": "MLC-T-ONC-014924",
  "term": "lutetium Lu 177 rsopatamab tetraxetan",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.",
  "synonyms": [
    "177Lu-DOTA-TLX591",
    "lutetium Lu 177-DOTA-TLX591",
    "DOTA-HUJ-591 LU-177",
    "lutetium Lu 177 rosopatamab",
    "lutetium Lu 177-DOTA-rosopatamab"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-rsopatamab-tetraxetan/"
}